

## INSIGHTS + NEWS

## Massachusetts Lawyers Weekly quotes Lou Ciavarra in “Inferences fail to support securities fraud class claim”

DECEMBER 24, 2018

A class action, *Emerson, et al. v. Genoea Biosciences, Inc., et al.*, alleges securities fraud could not survive a motion to dismiss, because the plaintiffs did not demonstrate the defendant drug company’s failure to disclose certain clinical test results was a material omission.

In its article, “Inferences fail to support securities fraud class claim,” *Massachusetts Lawyers Weekly* quoted Lou Ciavarra as saying:

Louis M. Ciavarra said it was hard to tell if the decision reflected a deficiency at the pleading stage that could be addressed in an amended complaint.

“The court certainly gives a road map on where the gaps are,” the Boston lawyer noted.

Ciavarra concurred that Saris’ willingness to dismiss “demonstrates the high burden plaintiffs have when bringing private securities suits.”

Continue reading “[Inferences fail to support securities fraud class claim.](#)”